Active Ingredient History

  • Now
Axelopran is a drug which is under development by Theravance Biopharma and licensed to Glycyx for all indications. It acts as a peripherally acting μ-opioid receptor antagonist and also acts on κ-, and δ-opioid receptors, with similar affinity for the μ- and κ-opioid receptors and about an order of magnitude lower affinity for the δ-opioid receptor. Recent data suggests that μ-opioid antagonists have a direct effect on overall survival in patients with advanced cancer.   Wikipedia

  • SMILES: NC(=O)c1cccc(c1)[C@H]2C[C@H]3CC[C@@H](C2)N3CCN(CC4CCCCC4)C(=O)[C@@H](O)CO
  • Mol. Mass: 457.62
  • ALogP: 2.26
  • ChEMBL Molecule:
More Chemistry
3-(8-(2-(cyclohexylmethyl(2,3-dihydroxypropionyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)benzamide | 3-endo-(8-(2-(cyclohexylmethyl-((s)-2,3-dihydroxypropionyl)amino)ethyl)-8-azabicyclo(3.2.1)oct-3-yl)benzamide | axelopran | td-1211


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue